Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)



Status:Withdrawn
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/18/2018
Start Date:December 7, 2017
End Date:September 2020

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy

Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor
Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy


Inclusion Criteria:

- Adult patients (older than 18 years at time of treatment) with high risk prostate
cancer who were treated with proton therapy at UFHPTI/Department of Radiation Oncology

- Patients treated between 6/10/2010 through 4/26/17 with at least 2 years follow up
We found this trial at
1
site
University of Florida Proton Therapy Institute
2015 Jefferson St
Jacksonville, Florida 32206
(904) 588-1800
Principal Investigator: Curits M Bryant, MD, MPH
Phone: 877-686-6009
University of Florida Proton Therapy Institute When the University of Florida Proton Therapy Institute opened...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials